Pfizer Reports Real-World Evidence for Vyndamax in Transthyretin Cardiomyopathy

Pfizer today presented real-world evidence for Vyndamax (tafamidis) in patients with transthyretin cardiomyopathy treated in clinical practice. The data showed that Vyndamax significantly reduced cardiovascular hospitalizations and all-cause mortality compared to untreated patients, consistent with clinical trial results. These real-world data support the use of Vyndamax in routine clinical practice.